Media
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
24-07-2019
Media AnnouncementsJuly 23, Chicago – PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma…
PolyActiva commences its first Phase I clinical trial
31-08-2018
Media AnnouncementsPolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently recruited first patients into its Phase I clinical study designed to show its glaucoma implant is safe and well tolerated…
Precise Control of Drug Loading and Release of an NSAID-polymer Conjugate for Long Term Osteoarthritis Intra-articular Drug Delvery
24-07-2017
Media Publications- Authors:
- Adrian Sulistio, Felisa Reyes-Ortega, Asha M. D’Souza, Sarah M. Y. Ng, David Valade, John F. Quinn, Andrew C. Donohue, Friederike Mansfeld, Anton Blencowe, Greg Qiao, Richard Prankerd, Stephen Quirk, Michael R. Whittaker, Thomas P. Davis, and Russell J. Tait
J. Mater.Chem B (2017), 5, 6221-6226. DOI: 10.1039/C7TB01518F, Published: 24 July 2017.
The Hydrolysis of Diclofenac Esters: Synthetic Prodrug Building blocks for Biodegradable Drug-Polymer Conjugates
08-09-2015
Media Publications- Authors:
- Feng Wang, Joshua Finnin, Cassandra Tait, Stephen Quirk, Igor Chekhtman, Andrew Donohue, Sarah Ng, Asha D'Souza, Russell Tait, and Richard Prankerd
J Pharm Sci (2016) 105, 773-785 (Research Article – Pharmaceutical, Drug Delivery and Pharmaceutrical Technology). DOI:10.1002/jps.24665, Published:8 September 2015.
PolyActiva raises AUD$9.2M in Series B venture funding
19-02-2013
Media AnnouncementsPolyActiva announced today that it has raised AUD $9.2 Million in a Series B financing round from a consortium of investors including the Medical Research Commercialisation Fund (MRCF) and Brandon Biosciences Fund 1 (BBF1) (both managed by Brandon Capital), Yuuwa Capital and additional participation from angel investors.